{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T15:10:05Z","timestamp":1749827405767,"version":"3.41.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.rmr.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:38:11Z","timestamp":1747251491000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence du tabagisme sur l\u2019efficacit\u00e9 de l\u2019immunoth\u00e9rapie dans les cancers pulmonaires de stade avanc\u00e9"],"prefix":"10.1016","volume":"42","author":[{"given":"F.","family":"Biney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9.","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Du Rusquec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Auliac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Assi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Anane-abrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2025.04.003_bib0145","unstructured":"The Global Cancer Observatory. Lung cancer Today. Source: Globocan 2020. [Internet]. Disponible sur: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/15-Lung-fact-sheet.pdf."},{"key":"10.1016\/j.rmr.2025.04.003_bib0150","article-title":"Pr\u00e9valence nationale et r\u00e9gionale du tabagisme en France en 2021 parmi les 18-75 ans, d\u2019apr\u00e8s le Barom\u00e8tre de Sant\u00e9 publique France","author":"Pasquereau","year":"2022","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"10.1016\/j.rmr.2025.04.003_bib0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2020.07.024","article-title":"Tobacco-related cancers in Europe: the scale of the epidemic in 2018","volume":"139","author":"Kulh\u00e1nov\u00e1","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2025.04.003_bib0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bmj.321.7257.323","article-title":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","volume":"321","author":"Peto","year":"2000","journal-title":"BMJ"},{"year":"2010","series-title":"Cancers et tabagisme passif [Internet]","key":"10.1016\/j.rmr.2025.04.003_bib0165"},{"key":"10.1016\/j.rmr.2025.04.003_bib0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00411-018-0741-x","article-title":"Quantitative health impact of indoor radon in France","volume":"57","author":"Ajrouche","year":"2018","journal-title":"Radiat Environ Biophys"},{"key":"10.1016\/j.rmr.2025.04.003_bib0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.04.003_bib0180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1\u00a0expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2025.04.003_bib0185","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.04.003_bib0190","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.rmr.2025.04.003_bib0195","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.04.003_bib0200","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.04.003_bib0205","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3\u00a0trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2025.04.003_bib0210","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1\u00a0and programmed death-ligand 1\u00a0blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2025.04.003_bib0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.rmr.2025.04.003_bib0220","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1\u00a0mutations and PD-1\u00a0inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.rmr.2025.04.003_bib0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2022.10.005","article-title":"Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy","volume":"174","author":"Justeau","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2025.04.003_bib0230","doi-asserted-by":"crossref","first-page":"220","DOI":"10.21037\/jtd-20-1953","article-title":"Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.rmr.2025.04.003_bib0235","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non\u2013small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2025.04.003_bib0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1\u00a0tumor proportion score of 50\u00a0% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2025.04.003_bib0245","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2019.11.015","article-title":"Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1\u00a0expression \u226550\u00a0%","volume":"31","author":"Gainor","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2025.04.003_bib0250","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.2005.04.8033","article-title":"Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity","volume":"24","author":"Toh","year":"2006","journal-title":"JCO"},{"key":"10.1016\/j.rmr.2025.04.003_bib0255","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2020.6362","article-title":"Proportion of never smokers among men and women with lung cancer in 7\u00a0US States","volume":"7","author":"Siegel","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2025.04.003_bib0260","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.3390\/curroncol29090492","article-title":"Tobacco use and response to immune checkpoint inhibitor therapy in non-small cell lung cancer","volume":"29","author":"Corke","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.rmr.2025.04.003_bib0265","doi-asserted-by":"crossref","first-page":"745859","DOI":"10.3389\/fcell.2021.745859","article-title":"The effect of smoking on the immune microenvironment and immunogenicity and its relationship with the prognosis of immune checkpoint inhibitors in non-small cell lung cancer","volume":"9","author":"Sun","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.rmr.2025.04.003_bib0270","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3390\/cancers14143439","article-title":"Association between nutritional status and treatment response and survival in patients treated with immunotherapy for lung cancer: a retrospective French study","volume":"14","author":"Gouez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.rmr.2025.04.003_bib0275","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2025.04.003_bib0140","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2008.16.6462","article-title":"Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic t-lymphocyte vaccine, in metastatic non\u2013small-cell lung cancer","volume":"26","author":"Barve","year":"2008","journal-title":"JCO"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842525001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:43:50Z","timestamp":1749825830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842525001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0761842525001822"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2025.04.003","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence du tabagisme sur l\u2019efficacit\u00e9 de l\u2019immunoth\u00e9rapie dans les cancers pulmonaires de stade avanc\u00e9","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}